Josep M. Campistol

Josep M. Campistol is presented throughout the volume as a Barcelona-based nephrologist whose work connects clinical transplantation, hepatitis C management, and the institutional organization of transplant medicine. His significance lies less in a narrated personal biography than in the range of roles attached to his name: co-editor of the book, contributor to a chapter on treatment for dialysis patients, and investigator of the difficult question of whether kidneys from hepatitis C-positive donors should be used for hepatitis C-positive recipients.

Identity and Institutional Position

Josep M. Campistol is listed among the volume’s co-editors alongside Jose M. Morales, Beatriz Domínguez-Gil, Michel Jadoul, and Lionel Rostaing. The editorial grouping places him within an international network spanning Madrid, Barcelona, Brussels, and Toulouse, while his own institutional location is consistently Barcelona. This positioning gives him a dual presence in the book: he helps shape the volume’s overall architecture, and he also contributes specialist knowledge to its central clinical problems.

His affiliation with Barcelona is repeated in the contents and author information. A chapter on the treatment of hepatitis C in dialysis patients identifies Josep M. Campistol as a Barcelona-based co-author with Nuria Esforzado. The book therefore associates him directly with the management of chronic viral infection in patients whose renal failure requires long-term dialysis, a population in which treatment efficacy, toxicity, survival, and access to transplantation are inseparable questions.

Clinical and Scholarly Work

Campistol’s contribution to the dialysis-treatment chapter places him in the therapeutic debate surrounding interferon-based treatment for patients with end-stage renal disease. In that setting, conventional interferon-alpha monotherapy produced sustained virologic response in roughly 33–45 percent of patients across different meta-analyses, although treatment dropout ranged from 17 to 30 percent. The more detailed synthesis of 428 hemodialysis patients found a 45 percent sustained virologic response, with better results when therapy lasted at least six months, was given at a dose of at least three million units three times weekly, was completed, and began in patients with low viral load.

The treatment evidence also makes the clinical problem that Campistol addresses unusually concrete. Discontinuation averaged 26 percent in one major analysis and ranged from 0 to 50 percent among the component studies. Higher doses were associated with more influenza-like symptoms and anemia, while conversion to a negative viral load during the first three months strongly predicted later success: 67 percent of those who achieved early viral negativity reached sustained virologic response, compared with 25 percent of those who did not. Campistol’s placement among the authors of this material associates him with a field in which therapeutic judgment depends on both virologic response and the burdens imposed by treatment.

The volume’s broader survival evidence supplies the stakes of that work. A meta-analysis of seven observational studies involving 11,589 dialysis patients estimated a 1.34 relative risk of all-cause mortality for patients with anti-HCV antibodies. Liver-related mortality was even more sharply differentiated, with an unadjusted relative risk of 5.89; hepatocellular carcinoma and cirrhosis were significantly more frequent causes of death among anti-HCV-positive dialysis patients. These findings explain why Campistol’s clinical field cannot be reduced to viral eradication alone: infection affects the patient’s prospects for survival, the timing of transplantation, and the evaluation of liver injury.

Transplantation from Hepatitis C-Positive Donors

Campistol is identified as a co-author of the chapter “Renal Transplantation from Donors with a Positive Serology for Hepatitis C,” together with Beatriz Domínguez-Gil, Nuria Esforzado, Amado Andrés, and Jose M. Morales. The author affiliations place him in the Nephrology Department of Hospital Clinic i Provincial in Barcelona, while the other contributors are connected with the Organización Nacional de Trasplantes and Hospital 12 de Octubre in Madrid. The collaboration thus joins clinical nephrology with national transplant organization and transplantation practice.

The chapter begins from a structural conflict: transplantation benefits approximately 100,000 people worldwide each year, yet donated organs remain insufficient for the waiting lists. At the end of 2009, the European Union had about 63,000 people waiting for an organ while approximately 28,000 transplant procedures were performed during the year. In the United States, almost 111,000 people were registered on the waiting list in May 2011, against roughly 28,000 procedures annually. Campistol’s research on hepatitis C-positive donor kidneys therefore belongs to a debate shaped not only by virology but also by scarcity, waiting time, and the consequences of discarding potentially usable organs.

The central medical hazard is transmission of hepatitis C through transplantation. Donors with positive hepatitis C serology are classified as non-standard-risk donors because of the possibility of donor-transmitted disease, and many centers refuse their kidneys outright; some countries impose technical or legal restrictions. Yet the chapter asks whether such organs should be wasted when the demand for kidneys greatly exceeds supply. Its evidence-driven approach examines safety and efficacy through center-based and registry-based studies, rather than treating donor seropositivity as an automatic exclusion.

Relations with Recipients and Treatment Policy

Campistol’s name is attached to research on transplantation of kidneys from donors with hepatitis C antibodies into recipients who were already anti-HCV-positive before transplantation. The relevant clinical logic is selective rather than universal: a hepatitis C-positive donor kidney is considered in relation to a recipient whose infection status, treatment options, liver condition, and waiting-list prospects have already been assessed. This framework distinguishes the risk of transmitting or intensifying infection from the separate danger of leaving a patient exposed to prolonged dialysis.

The chapter emphasizes that pretransplant antiviral treatment aimed at sustained virologic response is not compatible with a policy of using kidneys from hepatitis C-positive donors in hepatitis C-positive recipients. The limitation is practical as well as therapeutic. Interferon can produce a wide range of adverse events; some patients do not respond, withdraw, refuse treatment, or cannot afford it; and treatment may require exclusion from the waiting list while it is administered. For patients who remain RNA-positive and are not candidates for antiviral therapy, transplantation may nevertheless offer a more favorable course than continued dialysis. In that context, a hepatitis C-positive donor kidney may reduce time on the waiting list.

This argument is reinforced by the book’s comparison of replacement therapies. Although hepatitis C infection increases mortality among kidney recipients compared with noninfected recipients, transplantation still confers a survival advantage over remaining on dialysis when advanced liver injury is absent. In one analysis of listed hepatitis C-infected candidates, mortality was higher during the first six months after transplantation but fell markedly during months 7–84, when the hazard ratio was 0.32 compared with the waiting-list period. Campistol’s transplantation work thus occupies the intersection of two risks: the infectious risk associated with the donor organ and the mortality risk associated with continued dialysis and prolonged waiting.

Long-Term Significance

Campistol is also a co-author of a long-term study of kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. The study’s importance follows from the limits of short-term reassurance. Earlier reports found no adverse short-term effect of donor hepatitis C status in positive recipients, and some evidence showed shorter waiting times when seropositive recipients received kidneys from seropositive donors. Long-term experience was needed to test whether that apparent efficiency carried a delayed cost in graft or patient outcomes.

The surrounding evidence shows why the question remains clinically consequential. Hepatitis C-positive kidneys were reported to be 2.60 times more likely to be discarded than hepatitis C-negative kidneys. At the same time, the number of actively infected patients with end-stage renal disease and the waiting list had declined because of antiviral treatment and preventive strategies, leaving hepatitis C-positive donor kidneys increasingly likely to become surplus organs. The proposed response was organizational: centers should create approaches for transferring these kidneys to suitable recipients elsewhere, and preemptive transplantation could be considered for hepatitis C-positive recipients who were not going to receive interferon therapy.

Campistol’s work therefore represents a careful challenge to categorical exclusion. It does not erase the possibility of HCV transmission, superinfection, liver disease, or graft complications; rather, it places those dangers within a comparison that includes waiting-list mortality, treatment toxicity, organ scarcity, and the patient’s existing infection. His recurring presence across the volume’s editorial and clinical structures reflects a model of transplantation medicine in which virologic status is not an isolated label but one element in a changing chain of surveillance, treatment, allocation, and long-term outcome.